NIH bumps up support for neurological drug development

08/1/2013 | Genetic Engineering & Biotechnology News

The NIH will fund three new projects through its Blueprint Neurotherapeutics Network initiative, under which NIH staff form partnerships with awardee investigators. Sage Therapeutics won funding for Fragile X syndrome drugs, the Scripps Research Institute won an award for nicotine addiction treatments and the University of Utah won funding for drugs to treat age-related macular degeneration.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care